UPDATE: Why Did Perspective Therapeutics (CATX) Just Dropped 15% (And Why It Could Be Buying Opportunity)?

JPM Update: Trimming the fat, saving the cash, and doubling down on the data that matters?

Executive Summary: The Melanoma Option Paused

Just 48 hours after wowing us with NETs data at ASCO-GI (see most recent update post HERE), Perspective Therapeutics (CATX) dropped a strategic update for the J.P. Morgan Healthcare Conference that sent the stock tumbling 15%.

The Catalyst:

They are reportedly pausing the VMT01 (Melanoma) monotherapy arm.

Possible Interpretation:

The market often hates pauses. It can read them as failures. And in this case, the market isn’t necessarily wrong: the monotherapy arm likely didn’t show enough standalone efficacy to justify the cash burn. However, the 15% sell-off might be an overreaction that ignores the massive Alpha thesis the company recently supported for NETs.